Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369361 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL18954480 | 0.86 | ALDH1A1 (0.60) | ALDH1A1HPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL23579771 | 0.82 | KDM4E (0.77) | ALDH1A1HPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2368910 | 0.82 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2368556 | 0.82 | MAPT (0.67) | ALDH1A1KDM4ELMNASMN1; SMN2KMT2A | |
| SCHEMBL2368938 | 0.79 | ALDH1A1 (0.57) | ALDH1A1KDM4ELMNASMN1; SMN2KMT2A | |
| SCHEMBL2368317 | 0.79 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL8198010 | 0.78 | KMT2A (0.68) | ALDH1A1KDM4ELMNASMN1; SMN2KMT2A | |
| SCHEMBL688766 | 0.78 | ALDH1A1 (0.57) | ALDH1A1HPGDKDM4ELMNASMN1; SMN2 | |
| SCHEMBL8195420 | 0.77 | KMT2A (0.60) | ALDH1A1KDM4ELMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| EP-4081528-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115151550-A | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| US-8022076-B2 | Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents | XENTION LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| EP-1641803-B3 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-12-08 | — | — | EP | disclosed |
| EP-1641803-B1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1641803-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | ALDH1A1 2462/4885HPGD 372/4885KDM4E 3548/4885 |
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | ALDH1A1 247/4885HPGD 1231/4885KDM4E 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.